Effectiveness of Treatments That Alter Metabolomics in Cancer Patients—A Systematic Review
Metadatos
Mostrar el registro completo del ítemEditorial
MDPI
Materia
Metabolomics Metabolome Genetics Mycobiome Microbiota Neoplasms Cancer pain Pain and quality of life Oncometabolite
Fecha
2023-08-28Referencia bibliográfica
Navarro Ledesma, S.; Hamed-Hamed, D.; González-Muñoz, A.; Pruimboom, L. Effectiveness of Treatments That Alter Metabolomics in Cancer Patients—A Systematic Review. Cancers 2023, 15, 4297. [https://doi.org/10.3390/cancers15174297]
Patrocinador
University Chair in Clinical Psychoneuroimmunology (University of Granada); University Chair in Clinical Psychoneuroimmunology (PNI Europe)Resumen
Introduction: Cancer is the leading cause of death worldwide, with the most frequent
being breast cancer in women, prostate cancer in men and colon cancer in both sexes. The use of
metabolomics to find new biomarkers can provide knowledge about possible interventions based
on the presence of oncometabolites in different cancer types. Objectives: The primary purpose of
this review is to analyze the characteristic metabolome of three of the most frequent cancer types.
We further want to identify the existence and success rate of metabolomics-based intervention
in patients suffering from those cancer types. Our conclusions are based on the analysis of the
methodological quality of the studies. Methods: We searched for studies that investigated the
metabolomic characteristics in patients suffering from breast cancer, prostate cancer or colon cancer
in clinical trials. The data were analyzed, as well as the effects of specific interventions based on
identified metabolomics and one or more oncometabolites. The used databases were PubMed, Virtual
Health Library, Web of Science, EBSCO and Cochrane Library. Only nine studies met the selection
criteria. Study bias was analyzed using the Cochrane risk of bias tool. This systematic review
protocol was registered at the International Prospective Register of Systematic Reviews (PROSPERO:
CRD42023401474). Results: Only nine studies about clinical trials were included in this review
and show a moderate quality of evidence. Metabolomics-based interventions related with disease
outcome were conflictive with no or small changes in the metabolic characteristics of the different
cancer types. Conclusions: This systematic review shows some interesting results related with
metabolomics-based interventions and their effects on changes in certain cancer oncometabolites. The
small number of studies we identified which fulfilled our inclusion criteria in this systematic review
does not allow us to draw definitive conclusions. Nevertheless, some results can be considered as
promising although further research is needed. That research must focus not only on the presence of
possible oncometabolites but also on possible metabolomics-based interventions and their influence
on the outcome in patients suffering from breast cancer, prostate cancer or colon cancer.